NCT01678352View on ClinicalTrials.gov

Imiquimod and Tumor Lysate Vaccine Immunotherapy in Adults With High Risk or Recurrent Grade II Gliomas

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

November 8, 2017

Study Completion Date

November 8, 2018

Conditions
High Risk WHO Grade II GliomaRecurrent/Post-Chemotherapy WHO Grade II Glioma
Interventions
BIOLOGICAL

Tumor Lysate Vaccine

Cohort 1 Cohort 2 Cohort 3

DRUG

Imiquimod

Cohort 1 Cohort 2 Cohort 3

Trial Locations (1)

15232

University of Pittsburgh Medical Center, Pittsburgh

All Listed Sponsors
collaborator

University of Minnesota

OTHER

lead

Frank Lieberman

OTHER

NCT01678352 - Imiquimod and Tumor Lysate Vaccine Immunotherapy in Adults With High Risk or Recurrent Grade II Gliomas | Biotech Hunter | Biotech Hunter